|
|
Calcitonin is a naturally occurring hormone. In women who are at least 5 years beyond menopause, it slows bone loss and increases spinal bone density.
Inotropic therapy does not have a role in the treatment of most heart failure patients. These drugs can make patients feel and function better but usually do not lengthen the predicted length of their lives.
For pediatric patients, intravenous fluids are the most commonly cited products involved in medication errors that are reported to the USP.
Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.
The U.S. Preventive Services Task Force recommends that all women age 65 years of age or older should be screened with bone densitometry.